logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5870.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Export All Citations
Copyright © Médecins Sans Frontières
v2.1.5870.produseast1
World TB Day 2022—Progress on tools and care models amid global setbacks from Covid-19 | Collections | MSF Science Portal
World TB Day 2022—Progress on tools and care models amid global setbacks from Covid-19

World TB Day 2022—Progress on tools and care models amid global setbacks from Covid-19

Collection Content

Download Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.

  • All Assets (11)
  • CSV
  • BibTeX
  • EndNote
Download Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.

  • All Assets (11)
  • CSV
  • BibTeX
  • EndNote

See more collections

ASTMH Annual Meeting 2024

ASTMH Annual Meeting 2024

The American Society of Tropical Medicine & Hygiene (ASTMH) Annual Meeting is an international forum for the exchange of scientific and clinical advances in tropical medicine, hygiene and global health. The scientific content this year is 53% microbe focused, 15% clinically focused, 13% vector focused, 13% globally focused, and 6% intervention focused.

MSF and Epicentre are presenting on access and other challenges for children with visceral and cutaneous leishmaniasis, hurdles in malaria diagnostic testing, and ensuring equitable access to healthcare in conversations about financial sustainability.

This collection features research authored by the presenters and other topics highlighted at ASTMH.

Neglected tropical diseases

Neglected tropical diseases
World Hepatitis Day 2022

World Hepatitis Day 2022
View All Collections

Each year hundreds of thousands of people die from a neglected tropical disease, while many more suffer serious illness or lifelong disability. Yet as we mark World Neglected Tropical Diseases (NTD) Day on 30th January, global progress towards eliminating these diseases is threatened by shifting global health priorities and declining investment in the wake of the Covid-19 pandemic.


The content collection linked below offers a snapshot of MSF’s work on managing some of the most deadly NTDs, finding better tools and models of care for highly affected populations, and advocating for greater access to care and increased global funding. Several authors describe our programs and lessons learned from a decade of treating snakebite victims in sub-Saharan Africa. Two studies evaluate shorter, less toxic treatment for visceral leischmaniasis, while a policy analysis proposes critical steps towards eliminating this horrific disease in East Africa. Last, reports from Sokoto, Nigeria describe the collaborative development of a comprehensive model of care for noma.

Each year hundreds of millions of people suffer from chronic or acute liver disease caused by hepatitis viruses, and over one million die. To mark World Hepatitis Day (July 28th) we bring you a selection of MSF research exploring how to better prevent, identify and treat hepatitis infection in lower-income countries and emergency contexts where the burden is heaviest. For example, in a South Sudanese camp for displaced people—a type of setting where poor sanitation and water quality regularly lead to hepatitis E outbreaks—MSF and the Ministry of Health (MoH) are conducting the world’s first reactive vaccination campaign against this disease, and evaluating the process and outcomes. In Cambodia, MSF and MoH collaborators found that a simplified community-based model of care for hepatitis C was safe and highly effective in diagnosing patients and in curing them with new antiviral drugs. It was also cost-effective, according to studies in several countries and patient populations. And these new drugs were safe and effective even in patients also being treated for drug-resistant tuberculosis.
Journal Article
|
Research

Safety and effectiveness outcomes from a 14-country cohort of patients with multi-drug resistant tuberculosis treated concomitantly with bedaquiline, delamanid and other second-line drugs

Huerga H, Khan UT, Bastard M, Mitnick CD, Lachenal N,  et al.
2022-10-15 • Clinical Infectious Diseases
2022-10-15 • Clinical Infectious Diseases
BACKGROUND
Concomitant use of bedaquiline (Bdq) and delamanid (Dlm) for multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) has raised concerns about a potentially poor risk-ben...
Journal Article
|
Research

Whole genome sequencing has the potential to improve treatment for rifampicin-resistant tuberculosis in high burden settings: a retrospective cohort study

Cox HS, Goig GA, Salaam-Dreyer Z, Dippenaar A, Reuter A,  et al.
2022-02-16 • Journal of Clinical Microbiology
2022-02-16 • Journal of Clinical Microbiology
BACKGROUND
Treatment of multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB), although improved in recent years with shorter, more tolerable regimens, remains largely...
Journal Article
|
Research

Person-centred care and short oral treatment for rifampicin-resistant tuberculosis improve retention in care in Kandahar, Afghanistan

Mesic A, Ishaq S, Khan WH, Mureed A, Mar HT,  et al.
2022-01-03 • Tropical Medicine and International Health
2022-01-03 • Tropical Medicine and International Health
OBJECTIVES
To describe the effect of adaptations to a person-centred care with short oral regimens on retention in care for rifampicin-resistant TB (RR-TB) in Kandahar province, Afgh...
Journal Article
|
Letter

Urine LAM diagnostics can close the deadly testing gap for TB

Deborggraeve S, Menghaney L, Lynch S, McKenna L, Branigan D
2021-10-01 • International Journal of Tuberculosis and Lung Disease
2021-10-01 • International Journal of Tuberculosis and Lung Disease
Journal Article
|
Letter

TB research requires strong protections, innovation, and increased funding in response to COVID-19

Nyang'wa BT, LaHood AN, Mitnick CD, Guglielmetti L
2021-05-29 • Trials
2021-05-29 • Trials
When 2020 opened, approximately 11 million new tuberculosis (TB) cases and nearly 1.5 million TB-related deaths were predicted during the year. And, the gap between required and availabl...
Conference Material
|
Abstract

Early termination of randomisation into TB-PRACTECAL, a study examining novel six month, all-oral regimens for treatment of drug-resistant tuberculosis

Nyang'wa BT, Berry C, Motta I, Kazounis E
2021-05-19 • MSF Scientific Days International 2021: Research
2021-05-19 • MSF Scientific Days International 2021: Research
INTRODUCTION
Almost 500,000 people worldwide develop multidrug-resistant tuberculosis (MDR-TB) annually, with a treatment success rate of around 60%. Current treatment consists of up...
Conference Material
|
Video

Early termination of randomisation into TB-PRACTECAL, a study examining novel six month, all-oral regimens for treatment of drug-resistant tuberculosis

Berry C
2021-05-19 • MSF Scientific Days International 2021: Research
2021-05-19 • MSF Scientific Days International 2021: Research
Journal Article
|
Letter

A positive COVID-19 test is associated with high mortality in RR-TB-HIV patients

Mohr-Holland E, Daniels J, Douglas-Jones B, Mema N, Scott V,  et al.
2021-05-01 • International Journal of Tuberculosis and Lung Disease
2021-05-01 • International Journal of Tuberculosis and Lung Disease
Journal Blog
|
Perspective

The TB community in 2021—tired, frustrated, but hopeful

Berry C
2021-03-24 • BMJ Opinion (blog)
2021-03-24 • BMJ Opinion (blog)
The TB community continues to tackle one of the world’s oldest epidemics while struggling with the newest one, writes Catherine Berry
Journal Article
|
Commentary

Tuberculosis preventive therapy for children and adolescents: an emergency response to the COVID-19 pandemic

Mohr-Holland E, Douglas-Jones B, Apolisi I, Ngambu N, Mathee S,  et al.
2021-03-01 • Lancet Child and Adolescent Health
2021-03-01 • Lancet Child and Adolescent Health
Journal Article
|
Commentary

Introducing new and repurposed TB drugs: the endTB experience

Seung KJ, Khan UT, Varaine FFV, Ahmed SM, Bastard M,  et al.
2020-10-01 • International Journal of Tuberculosis and Lung Disease
2020-10-01 • International Journal of Tuberculosis and Lung Disease
In 2015, the initiative Expand New Drug Markets for TB (endTB) began, with the objective of reducing barriers to access to the new and repurposed TB drugs. Here we describe the major imp...